TPN Bag Recall Issued by Central Admixture Pharmacy Services
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
A single patient-specific TPN bag was recalled for incorrect formulation missing insulin listed on the label.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 24, 2026 and geographically references California. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles initiated a voluntary recall due to incorrect product formulation. The product did not contain insulin as listed on the label.
Which Products Are Affected
One TPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection. Lot #: 11-4909703-0-1, Exp 12/28/2025. Distributed in CA. Quantity: 1 bag.
What You Should Do
Consumers in possession of the affected product should follow instructions provided by the recalling firm or contact their healthcare provider.
Why This Matters
The recalled product failed to match its labeled formulation, posing a risk of incorrect medication administration.
Source
FDA recall number D-0524-2026, Class II, initiated December 27, 2025.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (836 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to May 24, 2026.
Frequently Asked Questions
Common questions about this FDA recall.